Literature DB >> 2994196

Thymopoietin to thymopentin: experimental studies.

G Goldstein, T K Audhya.   

Abstract

Thymopoietin is a polypeptide hormone of the thymus consisting of 49 amino acids. The pentapeptide thymopentin (TP-5) Arg-Lys-Asp-Val-Tyr, corresponding to amino acids 32-36 of thymopoietin, appears to represent the active site of thymopoietin in that it has all the biological activities of the native hormone. Thymopoietin is secreted by epithelial cells of the thymus and is pleiotropic in action, affecting neuromuscular transmission, induction of early T cell differentiation and immune regulation. The immuno-regulatory actions of thymopentin on peripheral T cells are mediated by intracellular cyclic GMP elevations in contrast to the intracellular cyclic AMP elevations induced in precursor T cells that trigger their further differentiation to T cells. Thymopoietin and thymopentin have the biological characteristics of being immunonormalizing in a number of animal model systems of immune dysbalance. These include immune dysbalances induced by thymectomy or the thymic involution associated with aging or by other procedures in thymus-intact animals. The normalizing action of thymopentin, whether the immune dysbalance be in the direction of hyper- or hyporesponsiveness, points to its potential utility in human diseases characterized by immune dysbalance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994196     DOI: 10.1007/bf02919050

Source DB:  PubMed          Journal:  Surv Immunol Res        ISSN: 0252-9564


  37 in total

1.  Radioimmunoassay for thymopoietin.

Authors:  G Goldstein
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

2.  Induction of T-cell differentiation in vitro by thymin, a purified polypeptide hormone of the thymus.

Authors:  R S Basch; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

3.  Contrasting effects of thymopentin and splenopentin on the capacity of female mice to reject syngeneic male skin.

Authors:  E H Goldberg; G Goldstein; D B Harman; E A Boyse
Journal:  Transplantation       Date:  1984-07       Impact factor: 4.939

4.  Immunoassay for bovine serum thymopoietin: discrimination from splenin by monoclonal antibodies.

Authors:  A Fuccello; T Audhya; M A Talle; G Goldstein
Journal:  Arch Biochem Biophys       Date:  1984-01       Impact factor: 4.013

5.  Serum thymic hormone activity with systemic lupus erythematosus.

Authors:  V M Lewis; J J Twomey; A D Steinberg; G Goldstein
Journal:  Clin Immunol Immunopathol       Date:  1981-01

6.  Effect of the TP5 analogue of thymopoietin on the rejection of male skin by aged and thymectomized female mice.

Authors:  E H Goldberg; G Goldstein; E A Boyse; M P Scheid
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

7.  Differentiation of T cells in nude mice.

Authors:  M P Schedi; G Goldstein; E A Boyce
Journal:  Science       Date:  1975-12-19       Impact factor: 47.728

8.  The thymus and neuromuscular function. A substance in thymus which causes myositis and myasthenic neuromuscular block in guineapigs.

Authors:  G Goldstein
Journal:  Lancet       Date:  1968-07-20       Impact factor: 79.321

9.  Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen.

Authors:  T Audhya; M P Scheid; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

10.  Immunological studies of aging. IV. The contribution of thymic involution to the immune deficiencies of aging mice and reversal with thymopoietin32-36.

Authors:  M C Weksler; J D Innes; G Goldstein
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

View more
  16 in total

1.  Human thymocytes bind to autologous and allogeneic thymic epithelial cells in vitro.

Authors:  K H Singer; L S Wolf; D F Lobach; S M Denning; D T Tuck; A L Robertson; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

2.  Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies.

Authors:  Ting Zhang; Xian-Yan Qin; Xi Cao; Wen-Hao Li; Tao Gong; Zhi-Rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-07-12       Impact factor: 6.150

Review 3.  The use of vaccines in renal failure.

Authors:  D W Johnson; S J Fleming
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis.

Authors:  M Malaise; P Franchimont; C Hauwaert; B Danneskiold-Samsoe; D Gross; H Gerber; H Gerschpacher; K Bolla
Journal:  Surv Immunol Res       Date:  1985

5.  Thymopentin treatment in a patient with pluriorificial pyoderma vegetans.

Authors:  M Simon; D Djawari; O P Horstein; K Bolla
Journal:  Surv Immunol Res       Date:  1985

6.  Effects of the immunomodulator diacetyl-splenopentin on antigen-induced arthritis in rabbits.

Authors:  R Bräuer; K Thoss; S Henzgen; G Waldmann
Journal:  Agents Actions       Date:  1992-01

7.  Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations.

Authors:  K H Hsieh; M F Shaio; T N Liao
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

8.  Cyclosporin A and the thymus. Immunopathology.

Authors:  W E Beschorner; J D Namnoum; A D Hess; C A Shinn; G W Santos
Journal:  Am J Pathol       Date:  1987-03       Impact factor: 4.307

9.  Immune regulation effect of lienal polypeptides extract in Lewis lung carcinoma-bearing mice treated with cyclophosphamide.

Authors:  Yan-Ping Wu; Jie Deng; Shu-Hua Ouyang; Zhong-Fu Mao; Guo-En Wang; Hiroshi Kurihara; Rong-Rong He; Yi-Fang Li
Journal:  Exp Biol Med (Maywood)       Date:  2017-10-27

10.  Immunomodulatory therapy with thymopentin and indomethacin. Successful restoration of interleukin-2 synthesis in patients undergoing major surgery.

Authors:  E Faist; A Markewitz; D Fuchs; S Lang; S Zarius; F W Schildberg; H Wachter; B Reichart
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.